MDM2 and essential thrombocythemia: The promising results of an open label phase I study of idasanutlin as a single agent in patients with PV and ET presented by Dr. Mascarenhaset al. in 2017 at ASH108 and the observation that in AML the patients with the highest overexpression of HDM2 are most responsive to therapy with idasanutlin109 suggest that MF patients, who express higher levels of HDM2 than those observed in PV, will respond well to idasanutlin.